Scancell Holdings PLC
LSE:SCLP
Scancell Holdings PLC
LSE:SCLP
Price:
10.1 GBX
Market Closed
Updated:
May 23, 2024
Scancell Holdings PLC
Research & Development
|
Scancell Holdings PLC
Research & Development Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Scancell Holdings PLC
LSE:SCLP
|
Research & Development
-£12.5m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-23%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Research & Development
-$124.4m
|
CAGR 3-Years
-137%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Research & Development
-$122.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Research & Development
-$159.2m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Research & Development
-£163.5m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Scancell Holdings PLC's Research & Development?
Research & Development
-12.5m
GBP
-12.5m
GBP
Based on the financial report for Oct 31, 2023, Scancell Holdings PLC's Research & Development amounts to -12.5m GBP.
What is Scancell Holdings PLC's Research & Development growth rate?
Research & Development CAGR 10Y
-23%
-23%
Over the last year, the Research & Development growth was -21%. The average annual Research & Development growth rates for Scancell Holdings PLC have been -38% over the past three years , -32% over the past five years , and -23% over the past ten years .
You don't have any saved screeners yet
